Amira Pharmaceuticals achieves another development milestone in its FLAP program

Amira Pharmaceuticals, Inc. announced today that it has achieved another development milestone in its FLAP program, which is partnered with GlaxoSmithKline. This milestone is related to the successful development of a solid dose formulation, which is critical for future development and commercialization activities.

"Achieving this milestone further demonstrates the success of our partnership with GSK and provides a meaningful economic benefit to Amira," said Hari Kumar, Chief Business Officer. "We are very pleased with our partnership and look forward to the continued success of this program at GSK."